UH Primary Care Institute
2016 Wellness Symposium

Release Date: 3/15/16
Expiration Date: 3/14/2019

PROGRAM AGENDA

Differentiating Headache Diagnoses and Interventions
Colleen Tomcik, MD
Presenter reports no financial relationship relevant to this presentation. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

 

Guideline Approach to Management of Diabetes
Faramarz Ismail-Beigi, MD, PhD
Presenter reports no financial relationship relevant to this presentation.

 

Treating Hypertension to Goal – Latest from SPRINT
Mahboob Rahman, MD 
Presenter reports no financial relationship relevant to this presentation.

 

Atrial Fibrillation – Rate vs. Rhythm Control 
Mauricio Arruda, MD
Presenter reports no financial relationship relevant to this presentation. Presentation includes discussion of unlabeled/investigational uses of a commercial product.

Guidelines for Managing Depression in Primary Care
Neal Goldenberg, MD, MPH
Presenter reports no financial relationship relevant to this presentation.

 

Obesity Overview – Prevention and Treatment
Leena Khaitan, MD, MPH  & Roy Buchinsky, MD
Presenters reports no financial relationship relevant to this presentation.

 

Hepatitis C – Screening and Treatment
S. Martin Cohen, MD
Presenter reports no financial relationship relevant to this presentation.

 

Target Audience

This activity is designed for health care providers of primary care services, including physicians, nurses and physician assistants. 

Learning Objectives

After participating in this activity participants will be able to:

  • Identify methods to treat obesity, including medical management and the various types of bariatric surgical procedures, and select the best option for the patient
  • Apply the Diabetes Care Guidelines to individual patients and implement strategies for early diagnosis and treatment of diabetes
  • Provide the best treatment options for patients with hypertension
  • Differentiate between rate and rhythm control for the treatment of atrial fibrillation, and identify the risks and benefits of each
  • Identify both pharmacologic and nonpharmacologic treatment options for a depressive patient, and recognize and appropropriately document a patient with depression
  • Manage patients with headache
  • Apply screening tools for identification of a person infected with Hepatitis C and identify the latest treatment options

Media

Recorded slides and audio presentation. Resource materials may include downloads of videos, print materials, slides or web pages. 

Planning Committee 

Roy Buchinsky, MD

Dr. Buchinsky reports no financial relationship with a commercial interest relevant to this activity.

Todd Zeiger, MD

Dr. Zeiger reports no financial relationship with a commercial interest relevant to this activity.

Accreditation Statement 

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Case Western Reserve University School of Medicine designates this enduring material for a maximum of 3.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each individual talk is designated for .5 AMA PRA Category 1 CreditTM.

Disclosure Statement

The policy of Case Western Reserve University School of Medicine CME Program (CWRU CME) requires that the Activity Director, planning committee members and all activity faculty (that is, anyone in a position to control the content of the educational activity) disclose to the activity participants all relevant financial relationships with commercial interests. Where disclosures have been made, conflicts of interest, real or apparent, must be resolved. Disclosure will be made to activity participants prior to the commencement of the activity. CWRU CME also requires that faculty make clinical recommendations based on the best available scientific evidence and that faculty identify any discussion of “off-label” or investigational use of pharmaceutical products or medical devices.

Instructions

To receive a statement of credit for up to 0.50 AMA PRA Category 1 Credit(s)TM you must:

  1. Review and reflect on the full content of the recorded session.
  2. Successfully complete the post-test. A score of 66% is required for passage.
  3. Complete the evaluation.

Your credits will be recorded by the CWRU CME Program and made a part of your cumulative transcript. 

Estimated Time to Complete this Educational Activity

Including review of any resource material and completion of the post-test, this activity is expected to take 3.5 hours to complete.

Fee

There is no fee for this program.

To contact the CME Provider: Email CWRU CME at medcme@case.edu

Medical Disclaimer

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.

Although every effort is made to ensure that this material is accurate and up-to-date, it is provided for the convenience of the user and should not be considered definitive.  Since medicine is an ever-changing science, neither the authors nor Case Western Reserve School of Medicine nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such information. 

Readers are encouraged to confirm the information contained herein with other sources.  This information should not be construed as personal medical advice and is not intended to replace medical advice offered by physicians. Case Western Reserve University School of Medicine will not be liable for any direct, indirect, consequential, special, exemplary, or other damages arising therefrom.

 

Resources

1)    Evers, Stefan. "Review of Existing Guidelines." Pharmacological Management of Headaches. Springer International Publishing, 2016. 45-52.

2)    Lecchi, Marzia, et al. "Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches." Expert opinion on drug metabolism & toxicology 10.10 (2014): 1381-1395.

3)    Codario, Ronald A., and N. J. Totowa. "Type 2 diabetes, pre-diabetes, and the metabolic syndrome." JAMA 306.2 (2011): 215.

4)    Handelsman, Yehuda, et al. "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan." Endocrine Practice (2011).

5)    Hagens, Vincent E., et al. "Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: Results from the Rate Control Versus Electrical Cardioversion (RACE) study." Journal of the American College of Cardiology43.2 (2004): 241-247.

6)    Fuster, Valentin, et al. "ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text." Europace 8.9 (2006): 651-745.

7)     NIMH STAR*D Study. http://www.nimh.nih.gov/funding/clinical-research/practical/stard/index.shtml

8)     American Psychiatric Association, clinical practice Guidelines for depression. http://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines

9)    Bardia, Aditya, et al. "Diagnosis of obesity by primary care physicians and impact on obesity management." Mayo Clinic Proceedings. Vol. 82. No. 8. Elsevier, 2007.

10) Buchwald, Henry, and Danette M. Oien. "Metabolic/bariatric surgery worldwide 2011." Obesity surgery 23.4 (2013): 427-436.

11) Shepard, Colin W., Lyn Finelli, and Miriam J. Alter. "Global epidemiology of hepatitis C virus infection." The Lancet infectious diseases 5.9 (2005): 558-567.

12) Ghany, Marc G., et al. "Diagnosis, management, and treatment of hepatitis C: an update." Hepatology 49.4 (2009): 1335-1374.